

FORM PTO-1449

ATTORNEY DOCKET NO.: F7649(V)

SERIAL NO.: 10/519,657

FILING DATE: December 22, 2004

CONFIRMATION NO.: 9203

Page 1 of 1

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

## U.S. PATENT DOCUMENTS

| EXAMINER INITIALS |   | DOCUMENT NO. | DATE     | NAME OF INVENTOR  | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|-------------------|---|--------------|----------|-------------------|-------|----------|----------------------------|
|                   | 1 | 5,821,217    | 10/13/98 | Forse et al.      | 514   | 2        |                            |
|                   | 2 | 2002/0019334 | 02/14/02 | Portman           | 514   | 2        |                            |
|                   | 3 | 2002/037830  | 03/28/02 | Berthelsen et al. | 514   | 2        |                            |
|                   | 4 | 2005/0238694 | 10/27/05 | Gerhardt et al.   | 424   | 439      |                            |

## FOREIGN PATENT DOCUMENTS

| EXAMINER INITIALS |   | DOCUMENT NO. | DATE     | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES OR NO |
|-------------------|---|--------------|----------|---------|-------|----------|-----------------------|
|                   | 5 | 629 350      | 12/21/94 | Europe  |       |          |                       |
|                   | 6 | 1 112 693    | 07/04/01 | Europe  |       |          |                       |
|                   | 7 | 01/85984     | 11/15/01 | PCT     |       |          |                       |
|                   | 8 | 2004/002241  | 01/08/04 | PCT     |       |          |                       |
|                   | 9 | 2 489 942    | 01/08/04 | Canada  |       |          |                       |

## OTHER DOCUMENTS

|  |    |   |
|--|----|---|
|  | 10 | Drucker, "Development of Glucagon-Like Peptide-1-Based Pharmaceuticals as Therapeutic Agents for the Treatment of Diabetes", Current Pharmaceutical Design, 2001, 7, pgs. 1399-1412 .   |
|  | 11 | Zander et al., "Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and $\beta$ -cell function in type 2 diabetes: a parallel-group study", the Lancet, Vol. 359, 3/9/02, pgs. 824-830. |
|  | 12 | Toft-Nielsen, "Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes", J. Clinical Endocrinol Metab 2001, 8/86(8): 3853-60.   |
|  | 13 | Sensi et al., "Chronobiological Aspects of Weight Loss in Obesity: Effects of Different Meal Timing Regimens", Chronobiology International, Vol. 4, No. 2, 1987, pp. 251-261.   |
|  | 14 | Harper, "Biological Properties of Whey Components A Review", The American Dairy Products Institute, 2001, pgs. 1-20   |
|  | 15 | Harper, "Biological Properties of Whey Components A Review", The American Dairy Products Institute, 2004, pgs. 1-44   |
|  | 16 | Nuttal et al., "Effect of Protein Ingestion on the Glucose and Insulin Response to a Standardized Oral Glucose Load", Diabetes Care, Vol. 7, No. 5, September-October 1984, pgs. 465-470.   |
|  | 17 | Abubakar et al., "Structural Analysis of New Antihypertensive Peptides Derived from Cheese Whey Protein by Proteinase K Digestion", J. Dairy Science, Vol. 81, No. 12, 1998, pgs. 3131-3138                                       |
|  | 18 | Co-pending Application: Applicant: Gerhardt et al., Serial No. 10/539,434; Filed: January 13, 2006; Attorney Docket No.: F7683(V)   |

EXAMINER

DATE CONSIDERED

EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THOROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.